|
|
| Research article summary (published 13 Aug 2009): |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Full Abstract
PURPOSE: We evaluated the efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. MATERIALS AND METHODS: Children with neurogenic detrusor overactivity 6 to 15 years old and previously receiving oxybutynin were assigned randomly at a 3:1 ratio to treatment with transdermal or oral oxybutynin. Initial dosages (transdermal 1.3, 2.9 or 3.9 mg daily; oral 5, 10 or 15 mg daily), based on pre-study dosages, were adjusted after 2 weeks and then maintained for 12 weeks. The primary efficacy end point was change from baseline to last observation in average urine volume collected by clean intermittent catheterization. RESULTS: A total of 57 patients were randomized to receive transdermal (41) or oral (16) oxybutynin. Safety data were available for 55 patients and efficacy data were available for 52. Mean +/- SD urine volume increased from 95 +/- 64 ml to 125 +/- 74 ml (p <0.001) with transdermal oxybutynin and from 114 +/- 75 ml to 166 +/- 92 ml (p = 0.002) with oral oxybutynin. Transdermal oxybutynin resulted in significant improvement in all measured urodynamic parameters. Similar trends and a significant increase in maximal cystometric bladder capacity were observed in the smaller oral oxybutynin group. There were 12 treatment related adverse events noted with transdermal oxybutynin (mild skin reaction) and 1 with oral oxybutynin (vasodilatation). The ratio of N-desethyloxybutynin-to-oxybutynin plasma concentrations was substantially lower with transdermal (1.4) than with oral (6.7) oxybutynin. CONCLUSIONS: Transdermal oxybutynin was a well tolerated and effective alternative to oral oxybutynin in treating neurogenic detrusor overactivity in children who previously tolerated oxybutynin.
Author information
Author/s: Cartwright, Patrick C (PC); Coplen, Douglas E (DE); Kogan, Barry A (BA); Volinn, Weining (W); Finan, Eileen (E); Hoel, Gary (G);
Affiliation: Division of Urology, University of Utah and Department of Pediatric Urology, Primary Children's Medical Center, Salt Lake City, Utah 84113, USA. patrick.cartwright(-atsign-)hsc.utah.edu
Journal and publication information
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
Journal: The Journal of urology (J Urol), published in United States. (Language: eng)
Reference: 2009-Oct; vol 182 (issue 4) : pp 1548-54
Dates: Created 2009/09/14; Completed 2009/10/02;
PMID: 19683731, status: MEDLINE (last retrieval date: 10/2/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
30 Dec 2006 - Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
7 Apr 2007 - Evolution of transdermal oxybutynin in the treatment of overactive bladder.
30 Dec 2007 - Transdermal drug delivery treatment for overactive bladder.
30 Aug 2006 - Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review.
16 Jul 2008 - Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
30 Jan 2004 - [Intravesical treatment of overactive bladder syndrome]
29 Sep 2006 - Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
15 Jan 2008 - [Changes in lower urinary tract function in children with hyperactive urinary bladder treated with combined therapy]
29 Apr 2007 - Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.
30 Aug 2008
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.